Generic vs Branded Pharmaceuticals in Nigeria — When Each Makes Sense

What "generic" actually means

A generic pharmaceutical is a product containing the same active ingredient, at the same strength and in the same dosage form, as a branded originator product. In Nigeria, generics must be registered with NAFDAC against the same pharmacopoeial standards (typically British Pharmacopoeia, BP) that apply to branded products. A NAFDAC-registered generic paracetamol 500mg tablet contains the same paracetamol BP that a branded paracetamol 500mg tablet contains. The drug is the same.

The differences between generic and branded products are typically in packaging, marketing investment, distribution channel arrangements, sometimes excipient choices (binders, fillers, coatings), and sometimes — for more complex molecules — minor formulation enhancements.

Bioequivalence — the standard underlying generic substitution

For any solid oral dosage form (tablet, capsule), regulators require the generic to demonstrate bioequivalence with the originator product — meaning the generic is absorbed into the bloodstream at a rate and to an extent that is statistically indistinguishable from the originator. This is the scientific basis for generic substitution: a bioequivalent generic delivers the same active ingredient at the same physiological concentration over time.

Bioequivalence is the answer to almost every distributor and pharmacy question about whether a generic "really works the same". For NAFDAC-registered generics manufactured to BP standard under GMP, the answer is yes — they work the same because they are designed and tested to deliver the same drug to the same place in the body at the same rate.

Why generics are cheaper

Generic pricing reflects what is and is not in the cost stack:

• No originator R&D cost recovery — branded originators recover decades of research investment through patent pricing. Once the patent expires, generics can be manufactured without paying for that research.
• Lower marketing spend — generics typically compete on price and reliability rather than brand-marketing campaigns.
• Manufacturer scale — established generic manufacturers run high-volume lines that drive cost down.
• Direct distribution — generics often reach the market through shorter channels (manufacturer → distributor → pharmacy) without multiple licensing tiers.

For the distributor, the implication is that generics deliver a stronger price-to-value ratio for buyers who are not paying for the brand premium — which is most Nigerian retail buyers.

Where branded still matters

Branded products are not always merely a brand premium. There are circumstances where branded purchase makes sense:

• Complex formulations — extended-release, controlled-release, transdermal, biologic and combination products are formulation-dependent and may genuinely differ between manufacturers.
• Narrow therapeutic index drugs — drugs where small dose differences matter clinically (some thyroid hormones, some anticoagulants) require careful generic-substitution decisions.
• Patient-driven brand loyalty — customers who have built trust with a specific brand often prefer to keep buying it, and serving that preference is legitimate retail.
• Hospital and tender supply — some institutional buyers specify branded products in tender documents.

For most common ambient pharmaceuticals (paracetamol, ibuprofen, metronidazole, co-trimoxazole, B-complex, folic acid, ciprofloxacin), NAFDAC-registered generics manufactured under GMP are fully appropriate and represent the bulk of retail volume in Nigeria.

How to talk to customers about generics

Distributors and pharmacies are routinely asked "is this the same as Panadol?" or "is this as good as Flagyl?" The honest answer:

• Yes, the active ingredient is the same. Paracetamol is paracetamol; metronidazole is metronidazole.
• Yes, both are NAFDAC registered (assuming both are — which is the precondition).
• Both are manufactured to the same BP standard. The drug content and quality are equivalent.
• The generic is more accessible on price — that is the practical benefit.
• If you have specifically preferred a branded product in the past, that is a legitimate choice — but on clinical grounds the generic is appropriate for almost every common indication.

What to avoid: framing the generic as inferior, framing the branded as a "better quality" product (without specific evidence), or making claims about effectiveness differences that bioequivalence data does not support.

The Nigerian distributor calculation

For a wholesale distributor, stocking both generics and selected branded SKUs is usually the right approach. A typical mix:

• NAFDAC-registered generics as the volume backbone — Dizpharm Paracetamol, Caregyl, Caretrim, Dizprofen, Ciprodiz, Relagesic, B Complex, Multivitamin, Folic Acid — for the price-sensitive buyer base that is most of Nigerian retail.
• Selected branded SKUs where customer preference is strong — chosen by your market, not by your supplier's wishlist.
• Margin tilt toward generics — generics typically deliver better unit margin to the distributor, even before the higher volume that price-driven demand brings.

The Dizpharm generic range is positioned exactly here — same active ingredients as the well-known branded products, NAFDAC-registered, GMP-manufactured, at distributor-friendly carton pricing.

Frequently asked questions